MARKET

CYCCP

CYCCP

Cyclacel Phar Pr
NASDAQ
5.23
-0.39
-6.94%
Opening 09:58 07/08 EDT
OPEN
5.50
PREV CLOSE
5.62
HIGH
5.64
LOW
5.22
VOLUME
5.06K
TURNOVER
--
52 WEEK HIGH
16.45
52 WEEK LOW
3.183
MARKET CAP
1.75M
P/E (TTM)
-0.0178
1D
5D
1M
3M
1Y
5Y
1D
Cyclacel Pharmaceuticals Secures $3 Million in Series F Preferred Stock Sale
Reuters · 16h ago
Reported Earlier: Cyclacel Pharmaceuticals To Acquire Fitters Sdn. Bhd. From FITTERS Diversified Via Share Exchange Representing 19.99% Of Cyclacel Stock Plus $1M Cash Payment
Benzinga · 22h ago
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
Reuters · 1d ago
Weekly Report: what happened at CYCCP last week (0630-0704)?
Weekly Report · 1d ago
CYCLACEL PHARMACEUTICALS INC - TO IMPLEMENT 1-FOR-15 REVERSE STOCK SPLIT EFFECTIVE JULY 7, 2025
Reuters · 6d ago
Weekly Report: what happened at CYCCP last week (0623-0627)?
Weekly Report · 06/30 09:37
Weekly Report: what happened at CYCCP last week (0616-0620)?
Weekly Report · 06/23 09:35
CYCLACEL PHARMACEUTICALS ANNOUNCES $3 MILLION PRIVATE PLACEMENT OFFERING OF CONVERTIBLE PREFERRED STOCK
Reuters · 06/20 20:30
More
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.

Webull offers Cyclacel Pharmaceuticals Inc stock information, including NASDAQ: CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.